Literature DB >> 9255901

Legionella jordanis pneumonia unresponsive to fluoroquinolones in a non-immunocompromised host.

V Baty1, B Hoen, H Schuhmacher, C Amiel, M Reyrolle, H Garin, P Canton.   

Abstract

Legionella jordanis has seldom been reported as a cause of infection in humans. We describe a case of pneumonia due to L. jordanis that occurred in a non-immunocompromised 74-year-old patient and failed to respond to a combination of ceftriaxone and ofloxacin. Cure was achieved only after an erythromycin-rifampin combination was started.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9255901     DOI: 10.3109/00365549709019054

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN: 0036-5548


  5 in total

1.  Legionella.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-04       Impact factor: 3.725

Review 2.  Tuberculosis pharmacotherapy: strategies to optimize patient care.

Authors:  Carole D Mitnick; Bryan McGee; Charles A Peloquin
Journal:  Expert Opin Pharmacother       Date:  2009-02       Impact factor: 3.889

Review 3.  Legionella jordanis lower respiratory tract infection: case report and review.

Authors:  Donald C Vinh; Richard Garceau; Gabriela Martinez; Debbie Wiebe; Tamara Burdz; Aleisha Reimer; Kathryn Bernard
Journal:  J Clin Microbiol       Date:  2007-05-09       Impact factor: 5.948

Review 4.  Rifampin combination therapy for nonmycobacterial infections.

Authors:  Graeme N Forrest; Kimberly Tamura
Journal:  Clin Microbiol Rev       Date:  2010-01       Impact factor: 26.132

5.  Evaluation of high-dose rifampin in patients with new, smear-positive tuberculosis (HIRIF): study protocol for a randomized controlled trial.

Authors:  Meredith Milstein; Leonid Lecca; Charles Peloquin; Denis Mitchison; Kwonjune Seung; Marcello Pagano; David Coleman; Elna Osso; Julia Coit; Dante Elmo Vargas Vasquez; Epifanio Sanchez Garavito; Roger Calderon; Carmen Contreras; Geraint Davies; Carole D Mitnick
Journal:  BMC Infect Dis       Date:  2016-08-27       Impact factor: 3.090

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.